

is there a time-release form of butyrate that gets into the intestines? not necessarily bio-available but "intestine available"?



# Time-Release Formulations of Butyrate for Intestinal Delivery

Butyrate, a short-chain fatty acid primarily produced by gut bacteria fermenting dietary fibers, plays critical roles in intestinal health, including supporting gut barrier function, regulating inflammation, and serving as an energy source for colonocytes. Several formulations have been developed specifically to ensure butyrate reaches the intestines intact, bypassing stomach acid degradation to deliver this beneficial compound where it can most effectively support intestinal health.

## Enteric-Coated Butyrate Formulations

Enteric coating represents one of the primary approaches to ensuring butyrate reaches the intestines. These formulations use pH-dependent coatings that resist the acidic environment of the stomach but dissolve in the more alkaline conditions of the intestines.

### Shellac and Cellulose-Based Coatings

A notable enteric-coated formulation uses hydroxypropyl methyl cellulose combined with shellac coating. This formulation was specifically designed for "extended and selective delivery of butyrate in the ileo-caecal region and colon" <sup>[1]</sup>. In clinical testing, researchers used <sup>13</sup>C-labeled butyrate to track its release and absorption through breath testing and found that this coating:

- Delayed the release of butyrate by 2-3 hours compared to uncoated tablets
- Successfully delivered sodium butyrate to the intestines of all tested subjects
- Released butyrate primarily in the ileo-cecal region and colon
- Maintained effectiveness even in Crohn's disease patients with variable intestinal transit times <sup>[1]</sup>

This approach addresses a key challenge in developing targeted butyrate delivery systems: the variable intestinal transit time in individuals, particularly those with inflammatory bowel diseases. The researchers confirmed that "no subject and Crohn's disease patient had an earlier release of <sup>13</sup>CO<sub>2</sub> after administration of the coated tablets," indicating that premature release in the upper GI tract was successfully avoided <sup>[1]</sup>.

### Commercial Enteric-Coated Products

Several commercial products use enteric coating technology to target butyrate delivery to the intestines. For instance, Butyrate Infusion utilizes enteric-coated capsules with sodium butyrate (200mg per capsule) where the "enteric coating protects butyrate from low pH in the stomach and ensures its intact transport to the intestine" <sup>[2]</sup>.

A different approach to enteric coating employs vegetable fats, specifically medium-chain triglycerides. This method shields butyrate from stomach acid and releases it only when lipase (a fat-digesting enzyme) is secreted in the duodenum, which is the initial section of the small intestine<sup>[3]</sup>. This strategy ensures targeted release beginning in the small intestine.

## **Extended-Release and Micro-Encapsulation Technologies**

Beyond basic enteric coating, more sophisticated time-release technologies have been developed to optimize intestinal delivery of butyrate.

### **Micro-Encapsulated Extended-Release Formulations**

Advanced formulations use micro-encapsulation technology to create extended-release granules. These are specifically "designed to shield the supplement from harsh stomach acid" and "engineered to release their contents precisely in the lower gastrointestinal tract, where it matters most" <sup>[4]</sup>. This approach provides more precise control over where and when butyrate is released throughout the intestinal tract.

The micro-encapsulation approach offers several advantages:

- Protection from stomach acid degradation
- Gradual release throughout the intestinal passage
- Potential for higher concentrations of butyrate in the distal intestine, where it may be most beneficial<sup>[5]</sup> <sup>[4]</sup>

## **Physiological Basis for Intestinal Targeting**

Understanding why these formulations are necessary requires knowledge of butyrate absorption and metabolism. In its natural state, unprotected butyrate would be:

- Rapidly absorbed in the upper gastrointestinal tract
- Metabolized before reaching the colon
- Lost as a therapeutic agent for the distal intestine<sup>[1]</sup>

Research has shown that "when uncoated oral formulation of NaB is administered... the compound is promptly dissolved and rapidly metabolized before reaching the colon" <sup>[1]</sup>. This explains why specialized delivery systems are crucial for intestinal targeting.

## **Absorption Mechanisms**

Once released in the intestine, butyrate is absorbed through multiple mechanisms:

- In its protonated form, it can cross the apical membrane through passive diffusion
- Since butyrate is primarily in ionized form at intestinal pH (5.5-6.7), it's mainly absorbed via active transporter systems
- Two primary transporters facilitate this process: sodium-coupled monocarboxylate transporter 1 (SMCT-1) and monocarboxylate transporter 1 (MCT-1)<sup>[5]</sup>

More than 95% of butyrate is absorbed by the intestinal tract, with concentrations highest in the distal intestine<sup>[5]</sup>. This highlights the importance of formulations that can deliver butyrate to these distal regions.

## **Clinical Evidence and Therapeutic Applications**

The effectiveness of these time-release formulations has been demonstrated in clinical studies. In one study, researchers used tauroursodeoxycholic acid as a biomarker of oro-ileal transit time to determine the site of butyrate release and absorption<sup>[1]</sup>. The results confirmed that properly coated butyrate formulations successfully delivered the active compound to the target areas of the intestine.

These targeted delivery systems have potential therapeutic applications, particularly in inflammatory bowel diseases. Research suggests that "this formulation may be of therapeutic value in inflammatory bowel disease patients due to the appropriate release of the active compound"<sup>[1]</sup>. Some studies have reported that "oral butyrate may improve the efficacy of oral mesalazine in active ulcerative colitis" and that "chronic feeding of this enteric coated NaB formulation can effectively induce clinical improvement/remission in mild Crohn's disease"<sup>[1]</sup>.

## **Expected Benefits of Intestinal Butyrate Delivery**

When butyrate successfully reaches the intestines, users may experience a progression of benefits:

### **Short-Term Effects (0-2 Weeks)**

Initial improvements in digestive health as colonocytes begin to utilize butyrate as an energy source, with some individuals noticing differences within days<sup>[6]</sup>.

### **Medium-Term Effects (2-4 Weeks)**

Continued strengthening of digestive function, potential resolution of increased intestinal permeability, restoration of healthy gut flora, and improved stool formation<sup>[6]</sup>.

### **Long-Term Effects (4+ Weeks)**

Development of a healthier gut structure, supporting immune function, healthy inflammatory response, cognitive clarity, and overall well-being<sup>[6]</sup>.

## **Conclusion**

Time-release forms of butyrate specifically designed for intestinal delivery exist in several formulations, including enteric-coated tablets/capsules, extended-release granules, and micro-encapsulated preparations. These formulations effectively ensure "intestine availability" rather than just systemic bioavailability, delivering butyrate to its primary site of action. The successful intestinal targeting of butyrate has been confirmed through clinical studies using biomarkers and isotope tracking, demonstrating that these specialized delivery systems can successfully navigate the variable transit times and conditions of the gastrointestinal tract to deliver butyrate where it's most needed.

Whether through pH-dependent dissolution, enzymatic triggers, or controlled-release technologies, these formulations represent significant advancements in maximizing the therapeutic potential of butyrate for intestinal health.

✱

1. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4146871/>
2. <https://www.julamedic.sk/en/products/butyrate-infusion/>
3. <https://help.bodybio.com/en-US/is-butyrate-enterically-coated-how-do-i-know-it-will-reach-the-gut-355810>
4. <https://www.longjuvity.com/products/extended-release-sodium-butyrate>
5. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9541926/>
6. <https://bodybio.com/products/butyrate>